Prognostic factors in early-stage NSCLC: Analysis of the placebo group in the MAGRIT study

Byoung Chul Cho, Tommaso De Pas, Haralabos Kalofonos, Qun Wang, Rodryg Ramlau, Ying Cheng, Fabiana Vitiello, Tanel Laisaar, Eric Vallières, Bartosz Kubisa, Sergey Orlov, Keunchil Park, Channa Debruyne, Johan Vansteenkiste

Research output: Contribution to journalArticle

Abstract

Background/Aim: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC). Patients and Methods: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models. Results: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC. Conclusion: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.

Original languageEnglish
Pages (from-to)1403-1409
Number of pages7
JournalAnticancer research
Volume39
Issue number3
DOIs
Publication statusPublished - 2019 Mar 1

Fingerprint

Non-Small Cell Lung Carcinoma
Disease-Free Survival
Placebos
Survival
Squamous Cell Carcinoma
Carcinoma
Far East
Proportional Hazards Models
Statistical Factor Analysis
Multivariate Analysis
Retrospective Studies
Prospective Studies
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Cho, B. C., De Pas, T., Kalofonos, H., Wang, Q., Ramlau, R., Cheng, Y., ... Vansteenkiste, J. (2019). Prognostic factors in early-stage NSCLC: Analysis of the placebo group in the MAGRIT study. Anticancer research, 39(3), 1403-1409. https://doi.org/10.21873/anticanres.13255
Cho, Byoung Chul ; De Pas, Tommaso ; Kalofonos, Haralabos ; Wang, Qun ; Ramlau, Rodryg ; Cheng, Ying ; Vitiello, Fabiana ; Laisaar, Tanel ; Vallières, Eric ; Kubisa, Bartosz ; Orlov, Sergey ; Park, Keunchil ; Debruyne, Channa ; Vansteenkiste, Johan. / Prognostic factors in early-stage NSCLC : Analysis of the placebo group in the MAGRIT study. In: Anticancer research. 2019 ; Vol. 39, No. 3. pp. 1403-1409.
@article{9800d30f417c4aa18d892644a4359912,
title = "Prognostic factors in early-stage NSCLC: Analysis of the placebo group in the MAGRIT study",
abstract = "Background/Aim: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC). Patients and Methods: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models. Results: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC. Conclusion: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.",
author = "Cho, {Byoung Chul} and {De Pas}, Tommaso and Haralabos Kalofonos and Qun Wang and Rodryg Ramlau and Ying Cheng and Fabiana Vitiello and Tanel Laisaar and Eric Valli{\`e}res and Bartosz Kubisa and Sergey Orlov and Keunchil Park and Channa Debruyne and Johan Vansteenkiste",
year = "2019",
month = "3",
day = "1",
doi = "10.21873/anticanres.13255",
language = "English",
volume = "39",
pages = "1403--1409",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

Cho, BC, De Pas, T, Kalofonos, H, Wang, Q, Ramlau, R, Cheng, Y, Vitiello, F, Laisaar, T, Vallières, E, Kubisa, B, Orlov, S, Park, K, Debruyne, C & Vansteenkiste, J 2019, 'Prognostic factors in early-stage NSCLC: Analysis of the placebo group in the MAGRIT study', Anticancer research, vol. 39, no. 3, pp. 1403-1409. https://doi.org/10.21873/anticanres.13255

Prognostic factors in early-stage NSCLC : Analysis of the placebo group in the MAGRIT study. / Cho, Byoung Chul; De Pas, Tommaso; Kalofonos, Haralabos; Wang, Qun; Ramlau, Rodryg; Cheng, Ying; Vitiello, Fabiana; Laisaar, Tanel; Vallières, Eric; Kubisa, Bartosz; Orlov, Sergey; Park, Keunchil; Debruyne, Channa; Vansteenkiste, Johan.

In: Anticancer research, Vol. 39, No. 3, 01.03.2019, p. 1403-1409.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic factors in early-stage NSCLC

T2 - Analysis of the placebo group in the MAGRIT study

AU - Cho, Byoung Chul

AU - De Pas, Tommaso

AU - Kalofonos, Haralabos

AU - Wang, Qun

AU - Ramlau, Rodryg

AU - Cheng, Ying

AU - Vitiello, Fabiana

AU - Laisaar, Tanel

AU - Vallières, Eric

AU - Kubisa, Bartosz

AU - Orlov, Sergey

AU - Park, Keunchil

AU - Debruyne, Channa

AU - Vansteenkiste, Johan

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background/Aim: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC). Patients and Methods: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models. Results: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC. Conclusion: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.

AB - Background/Aim: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC). Patients and Methods: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models. Results: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC. Conclusion: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=85062644717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062644717&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13255

DO - 10.21873/anticanres.13255

M3 - Article

C2 - 30842175

AN - SCOPUS:85062644717

VL - 39

SP - 1403

EP - 1409

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -